Joint Assessment of Intended and Unintended Effects of Medications: An Example Using Vascular Endothelial Growth Factor Inhibitors for Neovascular Age-Related Macular Degeneration

<table>Net health benefits accruing to patients with neovascular age-related macular degeneration when using vascular endothelial growth factor inhibitors according to annual risk of a nonocular hemorrhagic (NOH) event.</table>

Journal of Ophthalmology

fig4

Figure 4

Figure 4: Joint Assessment of Intended and Unintended Effects of Medications: An Example Using Vascular Endothelial Growth Factor Inhibitors for Neovascular Age-Related Macular Degeneration 

Figure 4 | Joint Assessment of Intended and Unintended Effects of Medications: An Example Using Vascular Endothelial Growth Factor Inhibitors for Neovascular Age-Related Macular Degeneration 